| Literature DB >> 31612129 |
Sebastian P Schwaminger1, Paula Fraga-García1, Marco Eigenfeld2, Thomas M Becker2, Sonja Berensmeier1.
Abstract
Downstream processing needs more innovative ideas to advance and overcome current bioprocessing challenges. Chromatography is by far the most prevalent technique used by a conservative industrial sector. Chromatography has many advantages but also often represents the most expensive step in a pharmaceutical production process. Therefore, alternative methods as well as further processing strategies are urgently needed. One promising candidate for new developments on a large scale is magnetic separation, which enables the fast and direct capture of target molecules in fermentation broths. There has been a small revolution in this area in the last 10-20 years and a few papers dealing with the use of magnetic separation in bioprocessing examples beyond the analytical scale have been published. Since each target material is purified with a different magnetic separation approach, the comparison of processes is not trivial but would help to understand and improve magnetic separation and thus making it attractive for the technical scale. To address this issue, we report on the latest achievements in magnetic separation technology and offer an overview of the progress of the capture and separation of biomolecules derived from biotechnology and food technology. Magnetic separation has great potential for high-throughput downstream processing in applied life sciences. At the same time, two major challenges need to be overcome: (1) the development of a platform for suitable and flexible separation devices and (2) additional investigations of advantageous processing conditions, especially during recovery. Concentration and purification factors need to be improved to pave the way for the broader use of magnetic applications. The innovative combination of magnetic gradients and multipurpose separations will set new magnetic-based trends for large scale downstream processing.Entities:
Keywords: food technology; industrial bioseparation; magnetic fishing; process design; protein purification; selective recovery; technical scale
Year: 2019 PMID: 31612129 PMCID: PMC6776625 DOI: 10.3389/fbioe.2019.00233
Source DB: PubMed Journal: Front Bioeng Biotechnol ISSN: 2296-4185
Figure 1Scheme highlighting the main criteria for a magnetic separation process intermeshed like cogs in a machine as they are dependent on each other. Parameters need to be chosen according to the target product in order to facilitate an efficient process.
Summary of magnetic separation strategies for biotechnological downstream processing.
| Magnetic collection | Fast, high throughput, process control | Recovery of MPs, multiple steps | Target purification (HGMS, OGMS) | Safarik et al., |
| Magnetic flocculation | Fast, filtration | Inclusion of impurities, recovery, polymerbeads | Harvest | Svoboda, |
| Magnetic flotation | Fast, separation, recovery | Aeration limitation, foaming, blockage | Purification, harvest (GAMS, GASE) | Li et al., |
| Magnetic sedimentation | Separation, low loss of MP, characterization | Small scale, low density beads, energy (Centrifuge) | Magnetic centrifuge | Scherer et al., |
| Magnetic sorting | Different shapes, sizes or magnetizations | Slow, small scale, expensive | Cell sorting | Miltenyi and Schmitz, |
| Magnetic stabilized bed | Continuous, homogeneous bed | Pressure drop, reactor size, field circulation, diffusion | Processing (MSBR) | Albert and Tien, |
The advantages and the disadvantages of magnetic separation strategies are shown. The separator setups where these strategies can be applied are displayed.
Figure 2Schemes of magnetic separator designs. A rotor-stator high-gradient magnetic separator (A) can be used for the purification of target proteins. Here, an electro magnet is used to establish high magnetic field gradients between holey plates (rotor and stator plates). In a first step, the target material is adsorbed to the magnetic particles and separated magnetically from the impurities in the separation chamber. In a second step, the magnetic particles are separated from the target protein, which is eluted (Fraga García et al., 2015; Schwaminger et al., 2019a). An open-gradient magnetic separator (OGMS) (B) in a form of a magnetic drum separator (MDS) is illustrated. Magnetic beads are separated from impurities with a magnetic drum and recovered with a scraper blade (Dong et al., 2015). In a magnetic filtration set-up (C), magnetizable wires, meshes, or bundles are placed in a magnetic field. Magnetic particles bind to these magnetizable matrices leading to a magnetizable filter cake, which improves the magnetic filter performance (Schwaminger et al., 2019b). During a gas-assisted magnetic separation (GAMS) process (D), a gas is bubbled through the reactor leading to the flotation of magnetic particles and attached target molecules, which can be collected with a magnet (Li et al., 2013). A magnetically-stabilized moving bed reactor (MSBR) is based on a rotating magnetic field around the reactor, which allows a fluidization of magnetic beads while they behave like a fixed bed in flow direction (E) (Zong et al., 2013). A magnetic decanter (F) allows the continuous transport of magnetic particles with the magnetized screw while impurities are not affected by the magnetic field and thus separated from the magnetic material (Lindner and Nirschl, 2014). A magnetic centrifuge (G) allows a fast separation due to the density difference and the magnetization of magnetic particles (Lindner and Nirschl, 2014).
Selection of commercially available magnetic beads for biotechnological purification and medical applications.
| Dynabeads | 1-4.4 | Carboxyl, streptavidin, antibodies, antigens, DNA/RNA | ION + PS shell | Purification, analysis | Invitrogen |
| SiMAG | 0.5-1 | OH, COOH, SO3H, PO3H2, NH2, DEAE, PEI, C1, C2, C8, C18, Protein A, streptavidin, heparin | ION + SiOx | Purification, analysis | Chemicell GmbH |
| SPHERO | 1-120 | Amino, carboxyl, diethylamino, dimethylamino, hydroxyethyl | ION + PS shell | Purification, analysis | Spherotech, inc. |
| Pure proteome | 0.3-10 | Carboxyl, streptavidin, protein, N-hydroxy-succinimide (NHS) | ION + Polymer | Purification, sorting | Emd millipore |
| Pierce beads | 1-10 | Streptavidin, protein, NHS, antibodies, glutathione | ION + polymer | Purification, analysis | Thermo scientific |
| Sera-mag | 1 | Carboxyl, streptavidin, neutravidin, oligo amine, protein | ION + PS shell | Purification | GE lifescience |
| Biomag | 1.5 | Carboxyl, streptavidin, amine, antigen, antibody | ION + SiOx | Purification, medical | Polysciences, inc. |
| GenoPrep | Hydroxyl | ION + SiOx | Purification | GenoVision | |
| MagaZorb | 1-10 | Hydroxyl | ION + Cellulose | Purification | Cortex biochem |
| MagneSil | 5-8.5 | Hydroxyl | ION + SiOx | Purification | Promega |
| MagPrep | 1 | Hydroxyl | ION + SiOx | Purification | Merck |
| MagSi | 1-5 | Hydroxyl | Purification | MagneMedics | |
| MGP | Hydroxyl | ION + Pore free glass shell | Purification | Roche Diagnostics | |
| M-PVA | 0.5-8 | PVA | ION + PVA | Purification | Chemagen |
| Sicastar | 1-6 | Maleic acid, Protein A + G, Carboxyl, Streptavidin, IDA/NTA | ION + PS-maleic acid copolymer | Purification | Micromod |
| BcMag | 1, 5 | Hydroxyl | ION + SiOx | Purification | Bioclone |
| BioMag | 1 | Hydroxyl | ION + SiOx | Purification | Bangs Lab |
| μMACS | 0.05 | Hydroxyl | ION + Dextran | Purification | Miltenyi |
| MPG | 5 | Hydroxyl | ION + Boro-silicate glass | Purification | PureBiotech |
| Nucleo-Adembeads | 0.1-0.5 | Hydroxyl | ION + Polymer | Purification | Ademtech |
| Scigen M | 3.5 | Hydroxyl | ION + Cellulose | Purification | Vector Lab |
| Feridex Combidex | 0.015-0.2 | Hydroxyl | ION + Dextran | Medical | Guerbet |
| Resovist Supravist | 0.02, 0.06 | Hydroxyl | ION + Carboxydextran | Medical | Schering |
| Clariscan Abdoscan | 0.02, 3.5 | Hydroxyl, Sulphonated styrene | ION + PEGStarch + SO3-PS-DVB | Medical | GE-Healthcare |
| VSOP-C184 | 0.007 | Carboxyl | ION + Citrate | Medical | Ferropharm |
Figure 3Toolkit for the selection of suitable magnetic beads according to the application. The choice of crude metal or ceramic particle and the strategy of stabilizing and functionalizing the magnetic particles play a decisive role for their application in bioseparation processes.
Summary of high gradient magnetic downstream processes at larger scales published since 2000.
| NdFeB magnet, 0.2 T, 2 L | Chitosan beads (47 μm, 65 μm) | Bovine trypsin | 10 L | Safarik et al., | ||||||
| Electro, 0.4 T | Bacitracin-linked beads (0.5-1 μm) | Cell-free | Savinase | Enzyme activity | Hubbuch et al., | |||||
| Electro, 0.4 T, 15 mL | Benzamidine-linked beads | Porcine pancreatin crude | Trypsin | 0.4 L, 1 g/L beads in, 2 g/L beads out | 62% | 3.5 | Hubbuch and Thomas, | |||
| Electro, 0.4 T, 5 mL | Dextran beads | Filtered extract of jack beans | Concanavalin | 125 mL, 4 g/L carrier | 99% | 69% | 3.8 | Heebøll-Nielsen et al., | ||
| Electro, 0.4 T, 5 mL | Cation-exchange beads | Clarified rennet bovine whey | Lactoperoxidase, lysozyme | 380 mL, 2.5 g/L carrier | 92% | 4.7 | 36 | Heebøll-Nielsen et al., | ||
| Electro, 0.4 T, 5 mL | Cation-exchange beads | Crude bovine whey | Lactoferrin, lacto-peroxidase, IgG | 6 g/L | Fractionation (3 proteins) | Heebøll-Nielsen et al., | ||||
| NdFeB magnet, 0.56 T, 4 mL | Cu-IDA beads | Crude sweet whey | Superoxide dismutase | 52 mL,7 g/L beads in, 21 g/L beads out 0.15–0.6 g/L protein | 86% | 21 | Meyer et al., | |||
| NdFeB magnet, 0.32 T, 46 mL | Epoxy-PVA beads (1–2 μm) | Lipase | Multicyclic activity | Schultz et al., | ||||||
| NdFeB magnet, 0.32 T, 182 mL | Functionalized beads | Crude sweet whey | Lactoferrin | 2.2 L, 5 g/L carrier in | 47% | 1.7 | 18.6 | Multicyclic recovery | Meyer et al., | |
| NdFeB magnet | DEAP beads | Clarified mare blood serum | Equine chorionic gonadotropin | 0.5 L | 5.4 | 975 | Müller et al., | |||
| Electro, R-S, 0.28 T, 160 mL | PAA beads (1.9 μm) | Filtered cheese, bovine whey | Lactoferrin, lactoperoxidase | 10 L (multiple cycles), 2 L per batch, 2,5 g/L carrier | 81 % (LPO) | 2.3 (LPO) | 73.4 (LPO) | Multicyclic recovery | Brown et al., | |
| Electro, R-S, 0.25 T, 980 mL | Cu-EDTA nano particles (22 nm) | Unclarified | His-GFP | 2.4 L, 100 g carrier, 22.3 g/L carrier in, 35 g/L carrier out, 8.5 g/L His-GFP | 96% | 93% | 0.3 | 2.5 | 12 g/h; 2.2 g/L h | Fraga García et al., |
| Electro, R-S, 0.25 T, 980 mL | DEAP beads | Pre-purified mare blood serum | Equine chorionic gonadotropin | 20 L, 60 g carrier, 4.5 g/L carrier | 56% | 6.7 | 2049 | Multicyclic recovery | Müller et al., | |
| NdFeB magnet, 0.56 T, 4 mL | Hydrophobic beads (0.8 μm) | Unclarified rabbit antiserum | Polyclonal antibody | 11.6 mL, 2.5 g/L IgG, 9.3 g/L lysate, 31.7 g/L carrier out | 81% | 72% | 3 | Gomes et al., | ||
| NdFeB magnet, 0.4 T, 122 mL | Bare Fe3O4 nano particles (12 nm) | Clarified | Glu-GFP | 1 L, 2 g, 2 g/L carrier 0.31 g/L lysate | 68% | 81% | 2.1 | Schwaminger et al., | ||
| Electro, R-S, 0.25 T, 980 mL | Bare Fe3O4 nano particles (12 nm) | Clarified | His-GFP | 2 L, 11 g, 5.5 g/L carrier, 1.5 g/L lysate | 91% | 38% | 2.5 | Schwaminger et al., | ||
| Electro, R-S, 0.25 T, 980 mL | Bare Fe3O4 nano particles (13 nm) | 5 L, 0.3 g/L carrier, 0.6 g/L cells | Fraga-García et al., | |||||||
| Electro, rod 1 T | Protein A agarose beads (90 μm) | CHO cell supernatant | Monoclonal antibody | 26 L clarified cell-free harvest, 1.9 L bead for 5 g/L mAb | 86% | Brechmann et al., |
Separator data, carrier type and diameter, conditions, target material, process scale, and performance indicators are shown. Generally, the magnetic flux densities correspond to the values in the air gap and the volumes to the void values. Broth and target molecules data as well as the carrier data correspond to the ones in the process feed. In each case, the highest processing values were selected. Purity (P), yield (Y), purification factor (PF), and concentration factor (CF) represent generally the total process results and combine several elution fractions.